Royalty Pharma plc
RPRX
$33.35
$0.200.60%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -4.28% | 5.13% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -4.28% | 5.13% | |||
| Cost of Revenue | -177.51% | 172.07% | |||
| Gross Profit | 61.87% | -45.78% | |||
| SG&A Expenses | 63.79% | 19.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -85.32% | 236.24% | |||
| Operating Income | 47.76% | -50.82% | |||
| Income Before Tax | 29.63% | -58.54% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 29.63% | -58.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -54.66% | 51.92% | |||
| Net Income | 14.47% | -61.72% | |||
| EBIT | 47.76% | -50.82% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 54.82% | -70.91% | |||
| Normalized Basic EPS | 86.72% | -66.25% | |||
| EPS Diluted | 54.20% | -70.87% | |||
| Normalized Diluted EPS | 40.69% | -55.32% | |||
| Average Basic Shares Outstanding | -26.06% | 31.58% | |||
| Average Diluted Shares Outstanding | -1.85% | -0.63% | |||
| Dividend Per Share | 4.76% | 0.00% | |||
| Payout Ratio | -0.11% | 1.60% | |||